Genprex Inc (NASDAQ:GNPX) CEO Rodney Varner tells Proactive the Texas-based biotech has been granted Fast Track Designation by the FDA for its Oncoprex immunogene therapy to treat lung cancer. Varner says the FDA validation is important, and gives the company more opportunities to meet with the FDA and facilitate the process of drug approval.
Full interview: Genprex gets FDA Fast Track for its Oncoprex combination therapy, raises $8M
Quick facts: Genprex, Inc.
Price: 2.135 USD
Market Cap: $70.13 m
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of Genprex, Inc. named herein, including the promotion by the Company of Genprex, Inc. in any Content on the Site, the Company receives from said...FOR OUR FULL DISCLAIMER CLICK HERE